| Patients with inherited rhythm disease | Class | References |
|---|---|---|
| Patients with certain inherited arrhythmia syndromes are at higher risk for AF and benefit from symptom-driven and periodic surveillance. |  | 123 |
| Evaluation should include non-invasive symptom-driven surveillance for patients at risk for AF and periodic non-invasive surveillance for asymptomatic patients. | | 232–234 |
| EPS to determine atrial AF substrate or susceptibility is not useful. |  | 123 |
| Patients with inherited rhythm disease | Class | References |
|---|---|---|
| Patients with certain inherited arrhythmia syndromes are at higher risk for AF and benefit from symptom-driven and periodic surveillance. | | 123 |
| Evaluation should include non-invasive symptom-driven surveillance for patients at risk for AF and periodic non-invasive surveillance for asymptomatic patients. | | 232–234 |
| EPS to determine atrial AF substrate or susceptibility is not useful. | | 123 |
| Patients with inherited rhythm disease | Class | References |
|---|---|---|
| Patients with certain inherited arrhythmia syndromes are at higher risk for AF and benefit from symptom-driven and periodic surveillance. | | 123 |
| Evaluation should include non-invasive symptom-driven surveillance for patients at risk for AF and periodic non-invasive surveillance for asymptomatic patients. | | 232–234 |
| EPS to determine atrial AF substrate or susceptibility is not useful. | | 123 |
| Patients with inherited rhythm disease | Class | References |
|---|---|---|
| Patients with certain inherited arrhythmia syndromes are at higher risk for AF and benefit from symptom-driven and periodic surveillance. | | 123 |
| Evaluation should include non-invasive symptom-driven surveillance for patients at risk for AF and periodic non-invasive surveillance for asymptomatic patients. | | 232–234 |
| EPS to determine atrial AF substrate or susceptibility is not useful. | | 123 |
